Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

ClinicalTrials.gov ID: NCT02603120

Public ClinicalTrials.gov record NCT02603120. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed Human Immunodeficiency Virus- 1 (HIV-1) infected adults.

Study identification

NCT ID: NCT02603120
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Gilead Sciences; Industry
Enrollment: 567 participants

Conditions and interventions

Conditions

HIV-1 Infection

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 11, 2015 (Actual)
Primary completion: May 9, 2017 (Actual)
Completion: Oct 23, 2019 (Actual)
Last update posted: Nov 12, 2020

2015 – 2019

United States locations

U.S. sites: 61
U.S. states: 22
U.S. cities: 51

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85012	—
Not listed	Beverly Hills	California	90211	—
Not listed	Los Angeles	California	90027	—
Not listed	Los Angeles	California	90033	—
Not listed	Los Angeles	California	90036	—
Not listed	Los Angeles	California	90069	—
Not listed	Oakland	California	94602	—
Not listed	Oakland	California	94609	—
Not listed	Palm Springs	California	92264	—
Not listed	Sacramento	California	95187	—
Not listed	Sacramento	California	95825	—
Not listed	San Leandro	California	94577	—
Not listed	Washington D.C.	District of Columbia	20009	—
Not listed	Washington D.C.	District of Columbia	20036	—
Not listed	DeLand	Florida	32720	—
Not listed	Fort Lauderdale	Florida	33308	—
Not listed	Fort Lauderdale	Florida	33316	—
Not listed	Ft. Pierce	Florida	34982	—
Not listed	Miami	Florida	33133	—
Not listed	Miami Beach	Florida	33139	—
Not listed	Orlando	Florida	32803	—
Not listed	Pensacola	Florida	32504	—
Not listed	Tampa	Florida	33614	—
Not listed	Vero Beach	Florida	32960	—
Not listed	West Palm Beach	Florida	33401	—
Not listed	Wilton Manors	Florida	33305	—
Not listed	Augusta	Georgia	30912	—
Not listed	Decatur	Georgia	30033	—
Not listed	Macon	Georgia	31201	—
Not listed	Savannah	Georgia	31401	—
Not listed	Honolulu	Hawaii	96813	—
Not listed	Chicago	Illinois	60613	—
Not listed	Chicago	Illinois	60657	—
Not listed	Louisville	Kentucky	40202	—
Not listed	New Orleans	Louisiana	70112	—
Not listed	Boston	Massachusetts	02118-2393	—
Not listed	Springfield	Massachusetts	01105	—
Not listed	Berkley	Michigan	48072	—
Not listed	Detroit	Michigan	48202	—
Not listed	Minneapolis	Minnesota	55415	—
Not listed	Kansas City	Missouri	64111	—
Not listed	St Louis	Missouri	63139	—
Not listed	Newark	New Jersey	07102	—
Not listed	Santa Fe	New Mexico	87505	—
Not listed	Buffalo	New York	14215	—
Not listed	New York	New York	10011	—
Not listed	The Bronx	New York	10467-2490	—
Not listed	Charlotte	North Carolina	28207	—
Not listed	Greenville	North Carolina	27834	—
Not listed	Huntersville	North Carolina	28078	—
Not listed	Cincinnati	Ohio	45267-0560	—
Not listed	Philadelphia	Pennsylvania	19107	—
Not listed	Columbia	South Carolina	29203-6840	—
Not listed	Austin	Texas	78705	—
Not listed	Dallas	Texas	75219	—
Not listed	Dallas	Texas	75246	—
Not listed	Houston	Texas	77004	—
Not listed	Houston	Texas	77098	—
Not listed	Longview	Texas	75605	—
Not listed	Seattle	Washington	98104	—
Not listed	Spokane	Washington	99204	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02603120, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2020 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02603120 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →